文献速递系统性红斑狼疮

贝利尤单抗治疗期间新发狼疮肾炎

De novo lupus nephritis during treatment with belimumab.
PubMed 文献 · Rheumatology (Oxford) · 2021-01-01

多中心真实世界队列纳入95例SLE患者,66例基线无肾受累者接受贝利尤单抗后9.1%出现活检证实的的新发狼疮肾炎,风险显著高于匹配对照(HR 10.7),而联用抗疟药呈保护性关联(HR 0.2)。

要点

  • 贝利尤单抗治疗与更高的新发狼疮肾炎频率和/或更短发生时间相关
  • 联用抗疟药与降低新发狼疮肾炎风险相关
  • 贝利尤单抗并未在有活动性非肾性SLE患者中预防狼疮肾炎

核心结论

  • 在标准治疗基础上加用贝利尤单抗未能预防活动性非肾性SLE患者发生狼疮肾炎,但联用抗疟药提示有利影响。

研究设计与样本

  • 2011至2017年间在五个欧洲学术中心纳入接受贝利尤单抗治疗的SLE患者95例并纵向随访,中位随访13.1个月。
  • 设年龄性别匹配、未暴露于贝利尤单抗的非肾性SLE对照,中位随访132.0个月。

主要发现

  • 66例基线无肾受累的贝利尤单抗治疗者中6例(9.1%)发生活检证实的新发狼疮肾炎,其中4/6为增殖性,中位随访7.4个月。
  • 对照组66例中2例(3.0%)发生新发狼疮肾炎(均为增殖性),分别于21和50个月出现。
  • 贝利尤单抗治疗与新发狼疮肾炎频率增加和/或时间缩短相关(HR 10.7;95% CI 1.7, 67.9;P=0.012)。
  • 贝利尤单抗联用抗疟药呈相反关联(HR 0.2;95% CI 0.03, 0.97;P=0.046)。

临床怎么用

  • 对接受贝利尤单抗的活动性非肾性SLE患者应警惕新发狼疮肾炎,并重视联用抗疟药的可能保护作用。

局限性

  • 样本量有限,对照随访时间远长于贝利尤单抗组,真实世界设计可能存在混杂。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: In light of reports of de novo LN during belimumab (BLM) treatment, we sought to determine its frequency and contributing or protective factors in a real-life setting. METHODS: Patients with SLE who received BLM between 2011 and 2017 at five European academic practices were enrolled (n = 95) and followed longitudinally for a median time of 13.1 months [interquartile range (IQR): 6.0-34.7]; 52.6% were anti-dsDNA positive, 60.0% had low complement levels, and 69.5% had no renal involvement prior to/at BLM initiation [mean disease duration at baseline: 11.4 (9.3) years]. Age- and sex-matched patients with non-renal SLE who had similar serological profiles, but were not exposed to BLM, served as controls (median follow-up: 132.0 months; IQR: 98.3-151.2). RESULTS: We observed 6/66 cases (9.1%) of biopsy-proven de novo LN (4/6 proliferative) among the non-renal BLM-treated SLE cases after a follow-up of 7.4 months (IQR: 2.7-22.2). Among controls, 2/66 cases (3.0%) of de novo LN (both proliferative) were observed after 21 and 50 months. BLM treatment was associated with an increased frequency and/or shorter time to de novo LN [hazard ratio (HR): 10.7; 95% CI: 1.7, 67.9; P = 0.012], while concomitant use of antimalarial agents along with BLM showed an opposing association (HR: 0.2; 95% CI: 0.03, 0.97; P = 0.046). CONCLUSION: Addition of BLM to standard-of-care did not prevent LN in patients with active non-renal SLE, but a favourable effect of concomitant use of antimalarials was implicated. Studies of whether effects of B-cell activating factor inhibition on lymphocyte subsets contribute to LN susceptibility are warranted.

来源:Rheumatology (Oxford),查看原文。版权归原作者所有。

引用

  1. Parodis I, Vital EM, Hassan SU, et al. De novo lupus nephritis during treatment with belimumab. Rheumatology (Oxford). 2021. PMID: 33341888. doi:10.1093/rheumatology/keaa796

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。